Child-resistant packaging is an important consideration in the development and commercialisation of certain pharmaceutical products. Its fundamental purpose is to make access significantly difficult for young children while allowing adults to use the package properly. Despite declining birth rates in many developed markets, demand for child-resistant packaging continues to grow. Industry analysts have pointed to a phenomenon sometimes described as “risk concentration per household”, where fewer children may be exposed to a growing number of potentially hazardous products within the home.
Growing Demand for Child-Resistant Packaging
Industry experts and market data point to a phenomenon known as “risk concentration per household,” where there are fewer children in the household, but households now contain a greater number of prescription medications, OTC products, cannabis-related products, and other potentially hazardous substances.1 The primary drivers include:
• Multi-generational households that increase interaction between children and medications and other products used by older adults
• Expanding regulations that continue to broaden the categories requiring childresistant packaging
• The emergence of look-alike products such as cannabis edibles and concentrated household products, and
• Growing expectations for sustainable and user-friendly packaging solutions.
Pharmaceuticals account for a substantial share of the child-resistant packaging market, while North America remains one of the most established markets for child-resistant packaging due to its long-standing regulatory framework.2 Together, these developments have made packaging strategy an increasingly important consideration for pharmaceutical manufacturers.
Regulatory Expansion Across Product Categories
Over the past decade, the scope of products subject to child-resistant packaging requirements has continued to expand in several markets. While prescription medicines have long been associated with safety packaging measures, regulatory authorities are increasingly evaluating additional product categories based on risk profiles, active ingredients and potential for accidental ingestion.
This trend is particularly visible in consumer healthcare products, cannabisderived formulations and certain highconcentration products. As new therapies are introduced and self-administration becomes more common, packaging is expected to contribute not only to product protection but also to risk mitigation.
For pharmaceutical companies, this evolving regulatory environment creates new challenges. Packaging decisions that were traditionally made late in the development process are increasingly being considered earlier, helping companies anticipate future requirements and avoid costly redesigns after product launch.
